Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (581-590 of 652) with videos related to

Pageof 66
Sort By:
The Lancet. Haematology|November 5, 2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Meral Beksac, Ludek Pour, et al.
The Oncologist|January 28, 2012
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of careTheodoros P Vassilakopoulos, Gerassimos A Pangalis, Andreas Katsigiannis, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
The Lancet. Haematology|May 13, 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trialMeletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, et al.
Leukemia|May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trialCharles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Hemasphere|November 15, 2019
Insights on Multiple Myeloma Treatment StrategiesMaría-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Pageof 66

Showing results (581-590 of 652) with videos related to

Sort By:
Pageof 66
The Lancet. Haematology|November 5, 2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Meral Beksac, Ludek Pour, et al.
The Oncologist|January 28, 2012
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of careTheodoros P Vassilakopoulos, Gerassimos A Pangalis, Andreas Katsigiannis, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
The Lancet. Haematology|May 13, 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trialMeletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, et al.
Leukemia|May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trialCharles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Hemasphere|November 15, 2019
Insights on Multiple Myeloma Treatment StrategiesMaría-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Pageof 66